Ignite Creation Date:
2025-12-17 @ 3:16 PM
Ignite Modification Date:
2025-12-23 @ 6:59 PM
Study NCT ID:
NCT00787150
Status:
COMPLETED
Last Update Posted:
2013-05-01
First Post:
2008-11-05
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: